September 21, 2017 8:41 AM ET

Biotechnology

Company Overview of Tivorsan Pharmaceuticals, Inc

Company Overview

Tivorsan Pharmaceuticals, Inc develops protein therapeutics for the treatment of neuromuscular disorders, including Duchenne muscular dystrophy and Becker muscular dystrophy. The company was founded in 2008 and is based in Providence, Rhode Island.

3 Davol Square

A301

Providence, RI 02903

United States

Founded in 2008

Phone:

410-419-2171

Key Executives for Tivorsan Pharmaceuticals, Inc

Chief Executive Officer and Director
Director of Finance and Director
Compensation as of Fiscal Year 2017.

Tivorsan Pharmaceuticals, Inc Key Developments

FDA Grants Orphan Drug Designation for Tivorsan Pharmaceuticals's Human Recombinant Biglycan in the Treatment of Duchenne Muscular Dystrophy

Tivorsan Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead investigational drug, human recombinant Biglycan, for the treatment of DMD. FDA Orphan Drug Designation provides special status to novel drugs and biologics that diagnose, treat or prevent rare or orphan diseases and disorders that affect fewer than 200,000 patients in the United States. The designation provides the drug developer with certain regulatory and financial incentives, including a seven- year period of U.S. marketing exclusivity, as well as tax credits for clinical research costs, assistance in clinical trial design and regulatory proceedings, and a waiver of FDA’s drug filing fees.

Tivorsan Pharmaceuticals, Inc. Raises Approximately $1.8 Million in Private Financing

Tivorsan Pharmaceuticals Inc. announced that it has raised approximately $1.8 million in private financing from a leading institutional investor, as well as other existing and new accredited investors. The financing will be used to fund research and development of Tivorsan’s lead compound, recombinant human Biglycan, for the treatment of DMD and other neuromuscular disorders, and for working capital and general corporate purposes. In addition, the financing will serve as a bridge to the company’s proposed Series D convertible preferred financing, which is expected to close in the second quarter.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Tivorsan Pharmaceuticals, Inc, please visit www.tivorsan.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.